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Abstract: Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative condition where loss of
motor neurons within the brain and spinal cord leads to muscle atrophy, weakness, paralysis and ultimately death
within 3–5 years from onset of symptoms. The specific molecular mechanisms underlying the disease pathology are
not fully understood and neuroprotective treatment options are minimally effective.
In recent years, stem cell transplantation as a new therapy for ALS patients has been extensively investigated, becoming
an intense and debated field of study. In several preclinical studies using the SOD1G93A mouse model of ALS, stem cells
were demonstrated to be neuroprotective, effectively delayed disease onset and extended survival. Despite substantial
improvements in stem cell technology and promising results in preclinical studies, several questions still remain
unanswered, such as the identification of the most suitable and beneficial cell source, cell dose, route of delivery and
therapeutic mechanisms. This review will cover publications in this field and comprehensively discuss advances,
challenges and future direction regarding the therapeutic potential of stem cells in ALS, with a focus on mesenchymal
stem cells. In summary, given their high proliferation activity, immunomodulation, multi-differentiation potential, and the
capacity to secrete neuroprotective factors, adult mesenchymal stem cells represent a promising candidate for clinical
translation. However, technical hurdles such as optimal dose, differentiation state, route of administration, and the
underlying potential therapeutic mechanisms still need to be assessed.
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Background
Amyotrophic lateral sclerosis (ALS), also known as Lou
Gehrig’s disease, is a rapidly progressive neurodegenera-
tive condition characterized by selective degeneration of
both upper motor neurons (MNs) in the motor cortex,
and lower motor neurons in the brainstem and ventral
horn of the spinal cord [1]. The estimated incidence of
ALS across the world is 2/100,000, with a prevalence of
up to 7.4/100000 [2].
The disease typically manifests during the sixth to sev-
enth decade of life leading to progressive muscle atro-
phy, weakness and paralysis. Affected individuals usually
die within 2 to 5 years after diagnosis due to respiratory
failure [2]. ALS is mainly sporadic in origin (SALS) but a
family history of the disorder can be found in ~10% of
cases. Hereditary forms of the disease (familial ALS or
FALS), are predominantly autosomal dominant and
rarely X-linked or recessive [2].
More than 20 mutated genes have been found to cause
FALS including SOD1 [3], TARDBP [4, 5], FUS [6, 7],
OPTN [8], VCP [9, 10], UBQLN2 [11], C9orf72 [12, 13]
and very recently TBK1 [14, 15]. SALS and FALS are
clinically indistinguishable, and since mutations in FALS
genes are also present in sporadic or isolated cases of
ALS, the disease can be interpreted as complex and
multi-factorial [16]. Nevertheless, clinical variability such
as rate of progression, site of onset (limb or bulbar) and
survival within patients and even relatives who carry the
same gene mutation highlight the importance of external
factors which may play a role in the susceptibility and
age of onset of the disease [16].
The specific molecular mechanisms behind ALS onset,
development and progression are not fully understood.
However, the discovery of causative inherited and de
novo gene mutations, together with the generation of
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the SOD1G93A transgenic mouse model uncovered im-
portant pathological mechanisms in ALS [17, 18]. The
SOD1G93A mice demonstrate many of the features seen
in human ALS pathology and represent the most widely
used in vivo model for the study of ALS. Indeed, axon
retraction, selective spinal motor neuron death, loss of
innervation of motor end-plates, muscular atrophy and
progressive motor deficit with terminal paralysis of hind
limbs are observed in this murine model [17, 18].
Several pathophysiological mechanisms have been pro-
posed including: cytoplasmic protein mis-localization
and aggregation [19], aberrant protein homeostasis [20],
RNA toxicity [13], dysregulation of RNA processing [21],
excitotoxicity mediated by excessive glutamate receptor
activation [22], mitochondrial dysfunction [23], endoplas-
mic reticulum stress response and microglial activation
[24], abnormal rearrangement of the cytoskeleton with
impaired axonal transport [25], and oxidative stress [26].
Moreover, the contribution of microglial cells, oligoden-
drocytes and astrocytes seems to be critical for the devel-
opment of the disease influencing significantly the speed
of disease progression after onset [27–31]. Indeed, ALS is
considered as a non-cell autonomous disease, where the
start and progression of motor neuron degeneration
seems to be influenced by complex interaction among dif-
ferent kinds of cells, together with the development of a
sustained inflammatory milieu [32]. Figure 1 summarizes
the major pathological mechanisms contributing to motor
neuron injury in ALS.
The complex heterogeneity of ALS, where several mo-
lecular mechanisms contribute to the pathology, enables
various opportunities for therapeutic intervention. How-
ever, the complexity of the disease and clinical variability
within patients inevitably makes the identification of a
universal single drug or therapy capable of correcting
the pathophysiology of ALS in its totality, very difficult.
Various therapeutic strategies are being experimentally
evaluated such as immunomodulation, approaches to
improve mitochondrial function, induction of autophagy
and anti-oxidant agents [16]. However, after over twenty
years of encouraging results in preclinical studies, no
efficacious treatment has been developed so far and
riluzole, the only recognised neuroprotective agent in
ALS, prolongs life expectancy by only approximately 3–
4 months [16].
During the last decade, progress in stem cell biology
has paved the way for potential cellular based therapy in
neurological diseases. Albeit still at an early stage and
with several issues to be solved, stem cell therapy holds
great promise for the treatment of ALS. Stem cells are a
population of cells which are defined by functional char-
acteristics. They are undifferentiated cells capable of
self-renewal, able to form clones in vitro and capable of
differentiation into mature cell lines of various tissues.
A B
Fig. 1 Molecular mechanisms in the pathology of amyotrophic lateral sclerosis. a Schematic representation of healthy spinal cord motor neuron.
b Schematic representation of ALS affected spinal cord motor neuron: 1) Astrocytes are not able to support neuronal functions and impaired
glutamate clearance leads to neuronal excitotoxicity; 2) Defects in protein degradation pathways and disturbances in RNA processing result in
protein aggregate formation, RNA toxicity and mitochondrial dysfunction; 3) The secretion of pro-inflammatory cytokines by predominant M1
activated microglia contributes to the development of an inflammatory milieu; 4) Failure of axonal architecture and transport functions, together with
the alteration of the physiological role of oligodendrocytes results in 5) synaptic failure, denervation and finally, muscle atrophy
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There are several potential advantages to the use of
stem cells in ALS:
1) The complexity of ALS pathology may not allow
the use of a single drug or targeted treatment;
2) The capability of stem cells to differentiate into
neuron-like cells and potentially replace the neuronal
population lost in ALS;
3) The degeneration of existing motor neurons could
be prevented by the release of neuroprotective trophic
factors and the immunomodulatory properties of trans-
planted stem cells, thus modifying the toxic microenvir-
onment in ALS.
This review will outline the recent progress relevant to
stem cell-based therapies in general in ALS, and will
focus on the therapeutic potential of mesenchymal stem
cells by discussing the major technical issues, challenges
and future directions.
Stem cell therapy in ALS
There are different types of stem cells which differ ac-
cording to the source, clonogenic capacity, differenti-
ation potential and availability.
Human embryonic stem cells (hESC)
Human embryonic stem cells (hESC) are derived from
the inner cell mass of the blastocyst and can indefinitely
propagate in vitro, preserving the capacity to differenti-
ate into any cell type of the three embryonic germ layers
(endoderm, mesoderm and ectoderm) [33]. For the first
time in 2005, Shin and colleagues obtained motor
neuron-like cells expressing markers such as islet1 and
choline acetyltransferase from hESC using conditioned
media containing basic fibroblast growth factor (bFGF),
retinoic acid (RA) and sonic hedgehog (Shh) [34]. The
survival, differentiation and beneficial neurotrophic sup-
port of motor neuron progenitors (MNP) derived from
hESC has also been demonstrated after lumbar intraspinal
transplantation into SOD1G93A mice and other MND
models [35, 36]. Wyatt et al., transplanted hESC derived
MNPs directly into the spinal cord of immunosuppressed
SOD1G93A mice, spinal muscular atrophy (SMA) Δ7SMN
pups and rats with spinal cord injury (SCI), demonstrating
the in vivo differentiation of the engrafted cells into a
mixed population of mature and immature motor neuron
cells [36]. The axons of the differentiated cells did not
reach the periphery, and the authors did not prove the
integration of the differentiated cells into the existing
neural circuit. However, the transplanted cells were able
to reduce motor neuron loss in proximity to the injection
site by actively releasing neurotrophic factors such as
neurotrophin-3 (NT-3) and nerve growth factor (NGF)
[36]. In particular, in SOD1G93A mice that received MNPs,
43 ± 5 endogenous neurons cranial to the injection site
survived until the end of the study (110 days old), in
comparison to the vehicle control group in which 27 ± 3
neurons were counted [36]. Yet, the use of hESCs in
the clinic is hindered because of ethical concerns, po-
tential tumorigenicity in vivo and the potential for graft
rejection [37].
Foetal neural progenitors (NSC)
Foetal neural progenitors (NSC) are multipotent stem
cells derived from foetal spinal cord or brain, capable of
in vitro self-renewal and able to differentiate into astrocytes,
neurons and oligodendrocytes. Given their partial matur-
ation state they have less propensity to form teratomas in
vivo [38]. Several studies investigated the safety and
therapeutic potential of spinal, intrathecal or intracra-
nial transplantation of hNSC in ALS rodent models
[39–41]. In particular, a well-characterized hNSC cell
line (NSI-566RSC) derived from an 8-week human foetal
spinal cord showed very promising results in transplanted
SOD1G93A rodents [42, 43].
In 2006, Yan et al. performed spinal cord injections of
NSI-566RSC cells in the ventral horn of 8-week-old
SOD1G93A mice at the lumbar level L4-L5, under com-
bined immunosuppression or CD4 antibodies [42]. Four
separate injections were carried out per mouse, with a
total of 8 × 104 cells. The authors showed that the graft
survived for more than two months after transplantation,
with most of the engrafted NSCs showing differentiation
into TUJ1+ neurons, and evidence of synaptic contacts
with host neurons [42]. Moreover, in mice injected with
live NSCs cells, disease onset was delayed by 15 days and
life span extended by 12 days in comparison to the control
group that received injections of dead cells. A statistically
significant later onset and a slowing of disease progres-
sion, was also confirmed by analysis of motor performance
[42]. The same group of authors, investigated the thera-
peutic potential of the NSCs-566RSC cell line after injec-
tion of around 8 × 105 cells into the lumbar spinal cord of
SOD1G93A rats at a pre-symptomatic disease stage [43]. In
this study, rats that received live NSCs showed an increase
in survival of around 11 days and a delay in disease onset
of 7 days when compared to the control placebo group.
The beneficial effect could be associated with the release
of neurotrophins such as glial-derived neurotrophic factor
(GDNF) and brain-derived neurotrophic factor (BDNF),
which in turn delayed the death of α-motor neurons in
the lumbar region [43].
Despite these encouraging data, the restricted number
of cells available for transplantation represents a potential
limitation for obtaining therapeutic efficacy in humans.
Induced pluripotent stem cells (iPSCs)
Induced pluripotent stem cells (iPSC) are an adult source
of pluripotent stem cells derived from somatic cells (e.g.
dermal fibroblasts) by forced genetic induction of four
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factors that preserve pluripotency in ESCs (KLF4, SOX2,
OCT4 and c-MYC) [44, 45]. The differentiation of human
iPSCs into electrically active motor neurons has been
accomplished by several groups both in vitro and in
vivo [46, 47].
Interestingly, Popescu et al. demonstrated in vivo dif-
ferentiation of human iPSC-derived neural progenitors
(NPs) in presymptomatic SOD1G93A rats following stem
cell injection into the ventral horns of the lumbar spinal
cord [48]. At 30 days post-transplantation human mito-
chondria positive cells displayed expression of the neur-
onal precursor marker doublecortin (DCX), indicating
the presence of undifferentiated progenitors. Substantial
differentiation into mature motor neurons could be ob-
served only after 60 days, with the majority of engrafted
cells expressing the neuronal marker MAP2 [48]. This
relatively long time is something to bear in mind, consid-
ering that transplantation was performed before disease
onset and NPs could survive and differentiate within a less
toxic environment in comparison to the symptomatic
stage. If cells were transplanted during disease progres-
sion, as would occur in the clinic, NPs may not have a
permissive environment and/or the necessary time to
differentiate into mature motor neurons. The therapeutic
potential of iPSC-derived NPs has also been investigated
in the SOD1G93A mouse model of ALS [49]. iPSC-derived
neural stem cells (NSCs), further selected for the ex-
pression of the integrin VLA4+, were transplanted either
by repeated (n = 3) intrathecal or weekly intravenous in-
jections. Intrathecal injection of cells extended survival by
10 days, while systemic delivery increased survival by
23 days, compared to control PBS injected mice [49]. The
molecular protective mechanism of iPSC-derived NSCs
may be attributed to the capacity of these cells to secrete
trophic factors such as GDNF, BDNF, NT-3 and TGF-α,
which in turn protects resident motor neurons and re-
duces astrogliosis [49].
The opportunity for reprogramming somatic cells into
neural stem cells (NSCs) could overcome the immune
rejection problem by autologous transplantation, and
bypass the ethical problems related to the use of ESCs
and foetal cells. However, several issues need to be ad-
dressed, such as reprogramming efficiency, epigenetic
memory and safety before translation of the use of
iPSCs into clinical practice.
Mesenchymal stem cells (MSCs)
Adult mesenchymal stem cells (MSCs) are stromal mul-
tipotent stem cells that can be derived from umbilical
cord, bone marrow, adipose tissue and peripheral blood
and have the capacity to differentiate into different
components of mesodermal origin (cartilage, bone, fat,
muscle and stroma) [50]. These cells can be expanded
and maintained by several passages in plastic-adherent
tissue culture. MSCs show fibroblast-like morphology,
they do not differentiate spontaneously and are character-
ized by the expression of specific surface markers [50]. In
addition to mesodermal commitment, several authors
showed the potential of bone marrow-derived MSCs
(BM-MSC) to differentiate into neuron-like cells, oligo-
dendrocytes and astrocytes [51–59].
Several characteristics make the use of MSCs very at-
tractive in ALS cell therapy. MSCs can be obtained and
expanded from adults relatively easily, bypassing the
ethical constraints related to the use of embryonic and
human foetal derived stem cells. Also, they are less im-
munogenic and can be harvested from ALS patients so
allowing both allogenic and autologous transplantation
[50]. Moreover, these cells are capable of homing to
areas of insult, possess immunomodulation and anti-
apoptotic properties, and are capable of secreting several
cytokines, extracellular matrix proteins and growth factors
relevant in neuroprotection and tissue repair [60]. Because
of these properties, mesenchymal stem cells are receiving
significant attention amongst researchers.
Proof-of-concept for MSCs therapy in the SOD1G93A
model of ALS
Several studies were performed in ALS rodent models in
order to investigate the potential of either human
(hMSC) or murine (mMSC) bone marrow-derived MSCs
(BM-MSCs) for cell therapy in ALS. Different approaches
have been tested by varying the delivery method, the
amount of injected cells, the timing of intervention, and
the differentiation state. Table 1 shows a summary of pre-
clinical studies described in the literature with injection of
BM-MSCs in ALS models.
Intravenous delivery
In 2007, Zhao and colleagues delivered 3 million hBM-
MSCs into 60 day pre-irradiated SOD1G93A mice by
intravenous infusion [61]. The recipient mice showed
about 14 days delay in disease onset, and prolonged sur-
vival of about 18 days in comparison to untreated mice.
Moreover, the decrease in motor performance (rotarod
test) was delayed by 3 weeks [61]. However, immunostain-
ing experiments showed that only a few transplanted cells
migrated and penetrated into the grey and white spinal
cord matter, surviving for no more than 20 days [61].
In another study, 1 million engineered hBM-MSCs
overexpressing neurogenin1 (Ngn1) were injected in the
tail vein of pre-symptomatic SOD1G93A mice [58]. Ngn1
is a transcription factor able to induce neuronal differen-
tiation in MSCs [58]. Two weeks after transplantation,
injected cells were found within the brain, spinal cord
and liver, and some cells had migrated into the spinal
cord parenchyma [58]. The neural induction of hMSCs
with neurogenin1 seemed to potentiate the migration
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capacity and survival of engrafted cells into the central
nervous system (CNS) of SOD1G93A mice, resulting in
enhanced and prolonged benefits [58]. The migration
capacity might be explained by high expression of che-
mokine receptors such as CCR2 and CXCR4, which
were significantly more expressed after neurogenin1 in-
duction. [58]. Interestingly, when MSCs were injected at
a pre-symptomatic stage, disease onset in the treated
group was delayed by 5 days with an increase in life span
of only 3 days. Conversely, when injected close to dis-
ease onset, Ng1-MSCs were able to increase survival by
about 7 days, suggesting the importance of the time of
intervention for stem cell therapy in ALS [58].
Furthermore, the Uccelli group demonstrated that
mouse BM-MSCs isolated from non-transgenic mice,
were therapeutically effective when transplanted during
the symptomatic stage of the disease in the SOD1G93A
mice [62]. In this study, mBM-MSCs expanded ex-vivo
for 8–15 passages, were transfected with the Luciferase
gene reporter vector pL-Luc-HI for in vivo tracking and
injected into the tail vein of SOD1G93A mice. The mice
that received the MSC transplantation showed an ex-
tended survival of 17 days, delayed decline in motor
performance and decreased weight loss when compared
to the control PBS-injected mice [62]. In addition, the
transplantation of MSCs alleviated the pathology of the
disease in the ALS spinal cord, by reducing astrogliosis
and microglial activation, and by restoring antioxidant
components such as glutathione-S-transferase and
metallothioneins to their baseline level of expression
and activity. However, the engraftment efficiency of
intravenous delivered cells within the CNS was very
low, with luciferase-positive cells almost completely ab-
sent twenty days post- injection. This suggested that
MSCs delivered by the intravenous route, can exert
clinically positive effects during the disease course that
do not correlate with the efficiency of long-term en-
graftment in the host [62].
Intrathecal delivery
Using a different approach, several authors have injected
a variable number of BM-MSCs directly into the cisterna
magna of pre-symptomatic SOD1G93A mice [63–66].
Direct injection into the CSF allows the obstacle of the
brain blood barrier (BBB) to be bypassed. Moreover, the
injected cells may migrate along the spinal cord possibly
reaching segments specifically affected by motor neuron
degeneration.
Indeed, it has been demonstrated that the injected
BM-MSCs were able to delay disease onset, improve
motor performance, ameliorate motor neuron death and
prolong survival in transplanted SOD1G93A mice [64–67].
These beneficial effects were enhanced by multiple intra-
thecal injections or by using a considerable number of
MSCs (1 × 106) [64, 65]. However, injected cells rarely mi-
grated into the parenchyma, suggesting a neuroprotective
effect of MSCs from the CSF [64, 65, 67]. In fact, it was
shown that injection of MSCS into the CSF of SOD1G93A
mice consistently inhibited microglial activation and the
release of inflammatory molecules, possibly by diffusion of
soluble factors where direct contact between cells is not a
requirement [67].
In 2009, Boucherie and colleagues, investigated the thera-
peutic potential of rat wild-type (WT) bromodeoxyuridine-
labelled BM-MSCs (BrdU-MSC) by intrathecal injection in
SOD1G93A transgenic rats, at disease onset [54]. Stem cell
transplantation in SOD1G93A rats resulted in a reduction in
the rate of disease progression, as the first signs of paralysis
were detected 2 weeks later in in comparison to control
mice. Moreover, treated mice showed reduced local inflam-
matory response and an increase in life span of 16 days
[54]. Interestingly, this is the only study to show a signifi-
cant trans-differentiation of MSCs into astrocyte-like cells
in vivo. Indeed, transplanted BrdU-MSCs were found to
penetrate into the grey matter of the ventral horns, and
stained positively for the astrocyte marker GFAP [54]. Re-
markably, around 40% of the BrdU-MSCs that successfully
migrated in proximity to motor neurons, co-localized with
the astrocyte marker, and about 30% of the GFAP-positive
cells were actually positive for the BrdU. This study demon-
strated a considerable local chimerization of the astroglial
population near the site of motor neuron injury in the lum-
bar spinal cord of SOD1G93A rats [54]. However, cell fusion
events with resident astrocytes cannot be excluded. Surpris-
ingly, the overall level of astrogliosis was not changed upon
MSCs treatment, and the loss of expression of the astrocyte
glutamate reuptake transporter (GLT-1), typically observed
in SOD1G93A rats, was not rescued [54].
The perineural net (PNN) is a specialized matrix struc-
ture present at a high density around motor neurons
and is fundamental in axon development as well as
neuronal plasticity [66]. Modification and deterioration
of the PNN has been observed in the spinal cord of
SOD1G93A rats during neurodegeneration [66]. Interest-
ingly, intrathecal delivery of hBM-MSCs into early post-
symptomatic SOD1G93A rats, resulted in partial rescue of
PNN structures suggesting a role of MSCs in reactivat-
ing CNS plasticity [66]. In this study, stem cell injection
increased survival of 14 days in comparison to the pla-
cebo group.
Boido et al. (2014) injected a total of 300,000 bisben-
zimide pre-labelled hMSCs into the cisterna lumbaris
(L5-L6 level) of early symptomatic SOD1G93A mice
[68]. Although the treated mice showed only a slight
delay in motor neuron loss and slowing of motor per-
formance decline, astogliosis and microgliosis were
consistently attenuated in recipient mice in comparison
to the controls [68]. Two weeks post-transplantation,
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transplanted cells were found mostly concentrated on
lumbar, thoracic and cervical meninges, but consider-
able numbers of bisbenzimide positive cells were found
in proximity to motor neurons within the spinal cord
[68]. It is noteworthy that the use of bisbenzimide as a
marker for cell transplantation has been questioned
since the dye may transfer from labelled cells to host
cells [69].
Intraparenchymal delivery
Other authors have attempted to inject human or mouse
MSCs directly into the dorsal horn of spinal cord of
SOD1G93A mice [70, 71]. In the Vercelli group experi-
ments, hMSCs were found to engraft, migrate to the ven-
tral horn close to α-motor neurons and survive more than
10 weeks after surgery, although without signs of differen-
tiation into neurons or astrocytes [70]. Also, male but not
female recipient mice showed a consistent (38%) increased
motor neuron survival as well as reduced gliosis and at-
tenuated astrocyte activation in comparison to control
mice [70]. Though the authors claimed an extended life-
span in male treated mice, not all of the experimental
groups were followed until the disease end-point, and a
Kaplan-Meier survival curve was not shown.
Intramuscular delivery
Since early pathologic mechanisms of disease involve
destruction of neuromuscular junctions before motor
neuron death, intramuscular injection of MSCs at early
stages of disease has also been proposed. hBM-MSCs,
genetically engineered to express green fluorescent pro-
tein (GFP) and to constitutively secrete GDNF, were
injected into the forelimb triceps brachii muscles of
pre-symptomatic SOD1G93A rats [72].
The intramuscular transplantation of MSCs did not
delay disease onset, however, survival was prolonged by
18 days. Furthermore, a reduction of endplate denerv-
ation in SOD1G93A rats was observed, when compared
to the control vehicle group [72]. However, MSCs were
not able to regenerate motor end-plates, nor to reduce
neuroinflammation [72]. Moreover, to obtain significant
survival and integration of MSCs in the host, the induc-
tion of focal muscle injuries was necessary.
MSCs in ALS: Clinical trials
Mazzini trials: Intraparenchymal delivery of autologous
BM-MSC
Despite the absence of any preclinical data, in 2001
Mazzini et al. embarked upon the first clinical trial in
order to evaluate the safety and feasibility of MSC injec-
tion into the spinal cord of sporadic ALS patients [73].
The study comprised the recruitment of 7 SALS patients
with spinal onset and severe lower limb impairment
without respiratory complications [73]. Autologous
mesenchymal bone marrow-derived stem cells were ex-
panded for 3–4 weeks under good manufacturing practice
(GMP) conditions and cytogenetic analysis, viability and
cytofluorimetric analysis for characterization of antigens
were carried out before infusion [73]. However, no de-
tailed data was provided.
In this study, following three hours in serum-free
medium, a variable number of cells ranging from 7 to
152 million were suspended in 1–2 ml of autologous
CSF and transplanted directly into the parenchyma of
spinal cord at thoracic level (T7-T9) [73, 74].
The patient follow-up was performed every 3 months
for six years. After surgery, no signs of increased neuro-
logical defects or toxicity were observed, indicating that
implantation into the spinal cord of ex vivo expanded
MSCs was safe and well tolerated by patients [73, 74].
To further validate the safety of the therapy, in 2010 a
second Phase I clinical trial was conducted in another
10 patients following the same protocol as described
above, with slight modifications [75]. Cells (11–122 mil-
lion) were transplanted in the anterior horn at the thor-
acic level (T4-T6) with different numbers of injection sites
(2 to 5) [75]. Two years post-surgery, no tumour forma-
tion, side effects or toxicity had been detected [75].
A long-term (9 years) safety study, concluded in 2012,
was carried out by the same authors on the basis of 19
ALS patients who underwent autologous MSCs implant-
ation in two separate phase I studies from 2001 to 2003
[76]. Importantly, magnetic resonance imaging (MRI)
analysis demonstrated no tumour formation or abnor-
mal cell growth, indicating that ex vivo expansion of
ALS patient-derived MSCs does not affect karyotype or
cellular senescence, making their use safe in the clinic
[76]. No data describing stem cell characterization were
shown and evidence of engraftment in post-mortem tis-
sues have not yet been described.
Blanquer trial: Intraparenchymal delivery of autologous
BMNC
Based on promising results in a mouse model of MND
[77], Blanquer et al. tested the safety and tolerability of
intraspinal transplantation of mononuclear cells derived
from autologous bone marrow (BMNC) in ALS patients
in an open label phase I clinical trial [78]. The study was
performed on 11 sporadic ALS patients with spinal onset
and no evidence of significant respiratory dysfunction [78].
Briefly, patients received two infusions of BMNC diluted
in 1 ml of saline solution into two different sites along the
posterior column of spinal cord at thoracic level after lamin-
ectomy, with the help of a specially designed micromanipu-
lator [79]. A variable number (138,000 to 60,287 × 106) of
BMNC cells, including an average of 2.77 × 106 CD34+,
2.31 × 106 CD117+ and 1.30 × 106 CD133+ cells, were
injected [78].
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After 1 year of follow up, no severe adverse effects or
acceleration of the disease progression related to the
treatment were observed, demonstrating the safety and
feasibly of the described procedure in ALS patients [78].
Moreover, spinal cord pathology on post mortem ma-
terial showed preservation of motor neurons at the in-
jection sites [78]. Interestingly, preserved motor neurons
were surrounded by spherical CD90+ cells negative for
neuronal markers, CD45 (hematopoietic stem cells) and
CD68 (monocytes/macrophages) markers [78]. These motor
neurons did not show any sign of degeneration [77, 78].
Karussis trial: Intrathecal and intravenous delivery of
autologous MSCs
In 2010, a phase 1/2 clinical trial was conducted in Israel
in 15 patients with multiple sclerosis (MS) and 19 ALS
patients [80]. In order to enhance the potential benefits
of MSC transplantation, after 40–60 days in culture, a
median of 60 million autologous MSCs were trans-
planted intrathecally in combination with a mean of 20
million MSCs delivered intravenously [80]. Also, in 9 pa-
tients MSCs were pre-labelled with ferumoxides in order
to track their fate in vivo by MRI [80].
At the end of 25 months of follow-up, no severe ad-
verse effects were registered in any of the patients, with
signs of disease stabilization in some patients during the
first 6 months after the intervention [80]. Furthermore,
MRI screening 24 h, 48 h, 1 and 3 months after the infu-
sion of cells, showed the presence of ferumoxides in
nerve roots, meninges and the parenchyma of the spinal
cord. However, these results are not conclusive of the
presence of MSCs in the CNS, since the contrast agent
can be ingested by phagocytes which have migrated to
inflammatory lesions [80]. Also, flow cytometry analysis
and subsequent proliferative response assay of peripheral
blood monocytes obtained from ALS patients 4 h and
24 h after infusion of MSCs, showed a dramatic increase
in CD4+ CD25+ regulatory T cells, coupled with a reduc-
tion in activated dendritic cells and lymphocyte prolifera-
tion, demonstrating the immediate immunomodulatory
properties of MSCs following transplantation [80].
Oh trial: Repeated intrathecal infusion of autologous
BM-MSCs
Very recently, a single open-label clinical trial was per-
formed in order to evaluate the clinical feasibility and
safety of two repeated infusions of autologous MSCs
into the CSF by lumbar puncture in 8 ALS patients [81].
At intervals of 26 days, 1 × 106 MSC cells per kg were
injected diluted in autologous CSF [81].
After 1 year, no deaths were recorded and the proced-
ure was considered safe, without long-term adverse ef-
fects [81]. In addition, CSF samples of two patients were
collected before both the first and the second injection
in order to evaluate cytokine levels. Il-10, TGF-β (I, II
and III) and IL-6 levels were increased after MSC trans-
plantation, while the level of the monocyte chemoattract-
ant protein 1 (MCP-1) was decreased [81]. A phase II
clinical trial in 64 ALS patients is on-going, with a placebo
control group allowing proper evaluation of efficacy and
safety (NCT01363401).
The same group performed repeated intrathecal MSC
injections in another 37 patients between 2007 and
2010, with the aim of identifying MSC markers capable
of predicting the response in ALS patients [82]. First,
they measured the level of various trophic factors in
MSC cultures from each patient by ELISA assay. They
then transplanted MSCs from different patients in the
SOD1G93A mouse model and analysed differences in on-
set, MN loss and immunoreactivity [82]. The authors
concluded that the beneficial effects (symptom improve-
ment and slowing of decline) observed in a proportion
of patients, were positively correlated with the increased
capacity of MSC cells to secrete VEGF, ANG and TGF-β
in vitro [82]. Moreover, the clinical efficacy observed in
some patients was confirmed also in SOD1G93A mice
which exhibited prolonged survival and lower levels of
neuroinflammation [82].
Adipose tissue: A fat tissue source for
mesenchymal stem cells
Mesenchymal stem cells represent an ideal source of
adult stem cells for cell therapy given their immunosup-
pressive nature, low potential for immunogenicity and
trans-differentiation capacity. However, the collection of
MSC from bone marrow is an invasive procedure which
can be painful and anaesthesia is often required [83].
Moreover, the proportion of stem cells within the total
cell population in bone marrow aspirate is usually about
0.001–0.002% which leads to extended culture times and
increased expense in order to obtain sufficient GMP
cells for clinical application [83].
Subcutaneous (buttocks and abdomen) and visceral
(omentum) white adipose tissue (WAT) may represent
an alternative source of stromal adult stem cells since
they can be obtained by minimally invasive, simple pro-
cedures such as liposuction or lipectomy and they are
relatively abundant, representing 1% of WAT cells after
processing [83–85]. Several names and abbreviations
have been used to refer to adipose-derived mesenchymal
stem cells. Here, the abbreviation ADSC will be used.
In the literature, the method for isolation of ADSCs
from human fat is performed following almost always
the same protocol described by Zuk and colleagues [83].
An illustration of the ADSC isolation method is showed
in Fig. 2.
Briefly, fresh lipoaspirate is washed extensively to elim-
inate red blood cells and contaminant debris, followed
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by extracellular matrix digestion with collagenase. After
enzymatic neutralization, the homogenate is centrifuged
to obtain the stromal-vascular fraction (SVF) pellet. The
pellet is then suspended in culture medium and left
overnight in a flask in the incubator at 37 °C with 5%
CO2. After incubation, cells are washed with phosphate
buffered saline (PBS) to remove residual non-adherent
cells. The culture medium usually consists of Dulbecco’s
modified eagle medium (DMEM) supplemented with
foetal bovine serum (FBS), penicillin and streptomycin.
In spite of some differences in the expression of clus-
ter of differentiation (CD) markers such as CD49d and
CD106, ADSC cells are phenotypically similar to BM-
MSC cells, showing fibroblast-like morphology, charac-
teristic expression of mesenchymal stem cell markers
(CD44+, CD105+, CD73+, CD90+, CD29+, CD45−, CD34
−, CD14− CD19−), lack of major histocompatibility com-
plex class II (MHC-II) and the capacity to differentiate
into osteoblasts, chondrocytes and adipocytes in specific
culture conditions [83]. Thus, hADSCs comply with all
the minimum criteria for the characterization of hMSCs,
established in 2005, by the International Society for Cel-
lular Therapy (ISCT) [86].
Like MSCs obtained from bone marrow aspirates,
hADSCs secrete several soluble factors such as BDNF,
NGF, hepatocyte growth factor (HGF), vascular
endothelial growth factor (VEGF), insulin-like growth
factor-1 (IGF-1) and basic fibroblast growth factor (bFGF)
that may contribute to neurotropism, neuroprotection
and tissue regeneration by paracrine mechanisms [87].
Even though the literature appears controversial, there
is evidence supporting the potential of ADSCs to trans-
differentiate into progenitors or mature cells of ecto-
dermal origin, therefore opening the way to a future in-
vestigation of the feasibility of cell replacement in
neurodegenerative disorders (Safford et al., 2002; Kram-
pera et al., 2007; Ahmadi et al., 2012; Feng et al., 2014).
In vitro neuronal differentiation capacity of ADSC
The capacity of ADSCs to differentiate in vitro into ma-
ture, stable and functional neurons is an open field of
debate among researchers. Table 2 summarises the pro-
tocols for neuronal differentiation of ADSCs published
in literature. Usually, the differentiation protocol consists
of expanding ADSCs as adherent cells for several pas-
sages, followed by induction with media containing differ-
ent cocktails of chemical agents, cytokines and growth
factors [88–92].
A different method to obtain neuron-like cells from
ADSCs is based on neurosphere formation capacity,
generally achieved by culturing cells in EGF and bFGF
conditioned serum-free media [93, 94]. A neurosphere
Liposuction PBS Wash
Adipose 
Infranatant
Oil and Adipocytes
Infranatant
Cell pellet
Centrifugation
0.075% Collagenase I
30-45 mins at 37°C
Wash and 
filtration
Subcutaneous fat
Culture the 
SVF
SVF
ADSCs
Self-renew
Fig. 2 Isolation process to obtain ADSCs from human lipoaspirate. Fresh lipoaspirate is extensively washed in PBS to remove blood and contaminants.
The adipose tissue is then enzymatically digested and the stromal vascular fraction (SVF) is obtained by filtration and centrifugation. Culture of the SVF
in standard plastic tissue culture flasks results in the selection and expansion of the adipose stem cell population
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is a cluster of cells containing neural precursors able to
proliferate and survive as floating and non-adherent
structures. The neurosphere can be dissociated, seeded
onto a poly-L-lysine feeder layer and differentiated by
adding neuronal induction components [93–95]. Alter-
natively, ADSCs are cultured in the presence of ESCs
or Schwann cells either in the presence or absence of
induction factors [91, 96]. In particular, when co-cultured
with Schwann cells, ADSCs showed long-lasting (12 days)
Schwann-like cell morphology and expression of myelin
protein [91]. Pre-irradiation of Schwann cells excluded
eventual cellular fusion artefacts [91]. Since the addition
of supernatant from Schwann cell cultures failed to differ-
entiate ADSCs, the authors speculated that the addition of
specific chemical components or growth factors to the
ADSC cultures, may promote the initial steps toward dif-
ferentiation in vitro, which can be completed in the appro-
priate microenvironment and by required cell-to-cell
interaction with mature cells in vivo.
The trans-differentiation of ADSCs towards motor
neuron-like cells has also been reported. In 2012, Abda-
nipour and Tirahini [97] induced rat ADSCs to trans-
differentiate into motor neuron-like cells by a two-step
protocol. ADSCs were committed to neural progenitors
expressing nestin, neurofilament 68 and neuro D by pre-
induction for 24 h with selegiline. Selegiline is an inhibi-
tor of monoamine oxidase B (MAO-B) which was used
to trans-differentiate BM-MSCs into dopaminergic
neural-like cells and proved to be a safer pre-inducer in
comparison to the toxic β-mercaptoethanol and butyl-
ated hydroxyanisole compounds, widely used for ecto-
dermal differentiation of MSC [97]. The maturation of
the pre-induced ADSCs into a motor-neuron phenotype
was then achieved by incubation with Shh and RA,
resulting in a differentiation efficiency of around 70%.
The resultant motor neuron-like cells (MNLCs) were
characterized by an initial and transient high expression
of oligo-2 and islet-1 (markers for early motor neuron
commitment during in vitro differentiation), followed by
a decrease in these two markers accompanied by an in-
crease in the expression of the motor neuron marker
HLBX9 [97]. Mature MNLCs, but not high HLBX9 ex-
pressing cells, were functionally tested for the capacity
to release pre-synaptic vesicles by staining and destain-
ing with the fluorescent probe FM1–43. Quantitative
analysis of vesicle release after stimulation, showed a 4-
fold increase in comparison to pre-induced ADSCs.
MNLCs, also formed innervation-like contacts with
myotubes in a co-culture in vitro system [97].
Very recently, the same authors proposed a different
method to obtain MNLCs from rat ADSCs [98]. ADSCs
were first converted into neurospheres by induction with
NM medium consisting of DMEM, B27, EGF and bFGF
for 7 days. Next, neural stem cells (NSC) were obtained
by neurosphere dissociation into single cells, and incuba-
tion for 10 days with NM supplemented with 10% FBS.
Maturation into motor neurons was achieved by incuba-
tion with Shh and RA for 5 days, followed by addition in
culture media of BDNF, GDNF, CTNF and NT-3 for an-
other 7 days [98]. During the maturation process of
ADSC-NSCs into motor neurons, an increase in the ex-
pression of islet-1, HB9 and ChAT was observed, with
MN-like cells positive for the neural marker MAP2 at
day 14 of maturation. These findings were documented
by both immunocytochemistry and RT-PCR. The func-
tional activity of mature MNLCs was investigated by
quantification of the release of synaptic vesicles by FM1–
43 loading and release experiments upon ion stimulation.
The synaptic vesicle activity correlated with changes in
intracellular calcium concentration and membrane
depolarization, as demonstrated by further investigations
utilizing calcium and voltage-sensitive dyes [98].
Is the trans-differentiation of ADSCs into neurons real?
The differentiation into neurons is commonly described
as morphological changes such as body retraction, bi-
or multi-polar shape and branching extension, and by
the expression of neuronal markers revealed by immu-
nohistochemistry (IHC), western blotting (WB) and
quantitative RT-PCR analysis. However, several studies
showed that the neural-like phenotype obtained by
chemical induction was a very fast but transient event
which may be a result of cytoskeletal rearrangement due
to the toxicity of compounds added into the induction
media [99, 100]. Furthermore, several neuronal markers
considered to confirm neuron maturation such as Nestin,
NSE, trk-A and vimentin are already present at low levels
in undifferentiated ADSCs [89, 90, 92, 95, 101].
Thus, morphological changes and expression of neur-
onal markers on the cell surface should not be consid-
ered as a definitive proof of neuronal differentiation, and
functional characterization (i.e. electrophysiology) is ne-
cessary. However, very few studies confirmed electrical
activity of ADSC-derived neurons by patch-clamp exper-
iments [92, 95].
In addition, the efficiency and reproducibility of differen-
tiation protocols described in the literature is low, and
neuronal induction of ADSCs gives rise to a heterogeneous
population of undifferentiated cells, neuron-like cells and
astroglial-like cells with different degrees of maturation
[91, 92]. Together with the fact that untreated ADSCs
often show slight expression of neuronal progenitor
markers, these results suggest the presence of specific cell
subtypes with different neuronal differentiation potential
[102]. This is supported by the existence of variability in
the secretome of hADSCs obtained from different donors
and maintained in separated cultures [103].
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In vivo studies with ADSCs
For the first time in 2013, the therapeutic potential of
ADSCs was investigated in the SOD1G93A mouse model
[104]. ADSCs were isolated from C57BL/6 GFP-
expressing mice, and a total of two million cells were
injected into the tail vein of B6SJL-SOD1G93A mice after
the first clinical signs of disease. The control group re-
ceived injection of PBS only as vehicle. mADSCs delayed
the motor performance decline and transiently attenuated
motor neuron death, in comparison to the controls. How-
ever, no differences in the degree of astrogliosis, nor in
survival were observed between the two groups [104]. The
authors claimed that GFP-positive cells were found to mi-
grate into damaged CNS areas, such as the grey matter in
the spinal cord, however, low magnification images
showing the entire spinal cord section or co-staining
with neuronal specific markers were not shown and hist-
ology on PBS-treated control spinal cord sections was not
performed. Finally, increased levels of trophic factors such
as GDNF and bFGF were found in spinal cord homoge-
nates of ADSC injected mice. This was despite the fact
that mADSC used in this study were not capable of
producing GDNF in vitro. It is likely that, in addition to
trophic factor production and secretion, ADSCs could
have an indirect biological effect by stimulating the
secretome of surrounding astrocytes, which are known
to produce GDNF [104].
Recently, another group tested the therapeutic poten-
tial of human ADSCs isolated from three healthy donors
aged 64, 69 and 84 [105]. Female transgenic SOD1G93A
mice before clinical evidence of disease received 1 × 106
hADSCs by intravenous (IV) or 2 × 105 hADSCs by in-
tracerebroventricular (ICV) injections. As a control, the
sham group received PBS only.
Rotarod test and paw grip endurance were monitored
and a reduction of 15% was considered as disease onset.
The endpoint (survival) was defined by the lack of a
righting reflex within 30 s after being placed on their
side [105]. The authors found that disease onset in mice
that received ICV injections was significantly delayed by
26 days, while in mice infused IV there was only an
11 day delay in disease onset. Remarkably, survival was
prolonged by 24 days and 9 days respectively in ICV and
IV mice when compared to the controls [105].
IHC evaluation of the spinal cord of ICV transplanted
mice revealed that 6.8% of transplanted cells survived up
to 4 weeks post-injection. However, only 0.7% migrated
to the grey matter of the lumbar spinal cord and very
few cells were positive for neuronal markers (MAP2 or
I-NFM). In contrast, after IV infusion very few undiffer-
entiated cells were found to engraft in the meninges of
the spinal cord [105]. In addition, when the TUNEL
assay was performed on spinal cord from ICV mice, re-
duced levels of apoptosis were seen in the anterior grey
matter compared to IV and control recipients. Also,
RT-PCR and ELISA assays on spinal cord homogenates
showed a significantly higher concentration of neurotrophic
factors in the ICV group in comparison to controls [105].
ELISA assay on the supernatant from hADSC cultures
showed high levels of neurotrophic factors that are relevant
in neuroprotection such as IGF-1 and VEGF [105]. The
anti-apoptotic effect was further confirmed in vitro by cul-
turing primary neural cells from normal mice with hADSC
conditioned media [105].
To date, these are the only two published studies using
ADSCs in an experimental model of ALS. However, the
therapeutic potential of ADSCs has been tested in other
experimental models of neurodegeneration. In particular,
the use of ADSCs showed encouraging results in animal
models of chronic stroke, Parkinson’s disease, Alzhei-
mer’s disease and traumatic brain injury and ageing
[106–109]. The use of ADSCs in ALS patients has not
been tested so far. However, currently two different clin-
ical trials are recruiting participants.
A clinical trial sponsored by The Royan Institute in
Iran will test the safety of intravenous injections of
ADSCs derived from healthy donors (2 million cells/kg) in
8 ALS patients (ClinicalTrial.gov identifier: NCT02492516).
The Andalusian Initiative for Advanced Therapies is
recruiting 40 ALS patients for a phase I/II, multicentre,
randomized, placebo controlled clinical trial to evaluate
the safety and efficacy of intravenous infusion of different
concentrations of autologous ADSCs (ClinicalTrials.gov
identifier: NCT02290886).
MSCs for ALS therapy: Proposed mechanisms of action
The in vitro differentiation of mesenchymal stem cells
into neuron-like cells brought great enthusiasm into the
idea of cellular replacement as a therapeutic strategy in
ALS. However, there are many practical issues to be
solved. The real trans-differentiation of MSCs into neu-
rons has been questioned and further investigation in
order to study molecular pathways and optimized proto-
cols enhancing the efficiency, stability and degree of
maturation are needed. Also, only a few studies have re-
ported MSCs or MSC-derived NSCs showing signs of in
vivo maturation when transplanted into mice (detailed
in the next section).
More importantly, for therapeutic efficacy, the trans-
planted cells should engraft, migrate to affected areas of
degeneration, survive, mature and integrate into the pre-
existing neuronal circuits forming synapses, extending
long axon projections to reach muscles and regenerating
neuromuscular junctions. All this must occur within a
hostile microenvironment where other motor neurons
are dying and activated microglia and astrocytes are sus-
taining an inflammatory milieu [30, 31].
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Moreover, different pathological mechanisms described
in ALS such as glutamate excitotoxicity [22], oxidative
stress [26] and loss of metabolic support [110] may affect
the viability of transplanted cells and inhibit maturation.
Finally, stem cell maturation and integration into the host
neuronal circuits could last a relatively long time, which
may not be compatible with the fast progression rate of
the disease.
Besides the challenge of cell replacement in ALS, in
recent years increased attention has been paid to the
“bystander effect” mechanism through which MSCs
could exert their therapeutic effect. Different mecha-
nisms have been proposed to explain the role of MSCs
in neuroprotection. Although the precise mechanisms
are still unknown, the secretion of anti-inflammatory cy-
tokines and growth factors by MSCs may influence the
progression of ALS in multiple ways, including endogen-
ous regenerative processes such as neuronal plasticity,
angiogenesis and axonal re-myelination [66, 111].
The delivery of growth factors such as BDNF, insulin-
like growth factor-1 (IGF-I), vascular endothelial growth
factor (VEGF) and glial derived neurotrophic factor
(GDNF) into ALS experimental models has been very
promising since these factors were shown to be neuro-
protective, improved motor function and prolonged
motor neuron survival [112]. However, translation into
the clinic failed to provide any beneficial effect in ALS
patients [112]. This is thought to be related to the small
amount of growth factor that effectively reached the
central nervous system (CNS) either because of an in-
ability to cross the blood brain barrier or because of the
short half-life after intravenous injection [112]. More-
over, intrathecal injections of growth factors did not re-
sult in relevant benefits for ALS patient [112].
The use of MSCs as “carriers” for the uninterrupted
supply of growth factors has been proposed, having shown
positive results in an ALS rodent model [113, 114]. In-
deed, MSCs transduced to overexpress specific growth
factors (GDNF, VEGF) or neuroprotective agents (e.g.
glucagon-like peptide 1) transplanted into SOD1G93A ro-
dent models, significantly preserved neuromuscular junc-
tions, attenuated motor neuron death, improved motor
function, delayed symptom onset and prolonged survival
[113, 114]. Recently, the Karussis group and Brainstorm-
Cell therapeutics completed an open lab phase 1/2 clinical
trial evaluating the safety and feasibility of intrathecal
injections of MSCs induced to secrete neurotrophic fac-
tors (BDNF, GDNF) (NurOwn™) in 12 ALS patients
(NCT01051882). Although, no results have been pub-
lished so far, the details of another two separate active
clinical trials can be found at ClinicalTrials.gov. An open
label phase 2a escalating-dose trial (NCT01777646) and a
phase 2 randomized, double-blind trial (NCT02017912)
in order to evaluate safety and efficacy of multiple
intramuscular and intrathecal combined injection of
NurOwn™ cells into ALS patients are reported as in
progress.
Through paracrine activity and cell-to-cell contacts,
MSCs were able to induce astrocytes and glial cells to
secrete enhanced levels of GDNF, VEGF and CNTF (cil-
iary neurotrophic factor) both in vitro and in the
SOD1G93A mice, resulting in anti-apoptotic effects and
motor neuron protection [104, 115].
Another potential mechanism by which MSC could
participate in tissue repair, is in the secretion of exosomes
[116]. Exosomes are membrane vesicles originating from
the inner cell membrane, which contain proteins, mRNAs
and microRNAs. The content of exosomes, after their se-
cretion from stem cells, could be transferred to neigh-
bouring cells and mediate a plethora of biological
pathways from free radical scavenging to the activation of
self-regenerative programmes [117]. Interestingly, exo-
somes derived from murine adipose derived stem cells
(ADSCs), were able to protect both naïve and SOD1G93A
transfected (overexpression of the human SOD1 gene with
the G93A mutation) NSC34 motor neuron-like cells from
oxidative stress in an in vitro culture system, with a sig-
nificant reduction of apoptosis events and an increase in
cell viability [118].
MSCs may act by modulating astrocyte dysfunction
since they showed the ability to induce expression of
glutamate re-uptake transporter 1 (GLT1) and inhibit
caspase-3 cleavage in SOD1G93A mutated astrocytes,
thus limiting excitotoxicity [119].
Several studies on experimental models of ALS dem-
onstrated the capacity of MSCs to attenuate astrogliosis
[67, 68, 70]. When transplanted into SOD1G93A mice,
MSCs may exert immunomodulatory effects indirectly
by stimulating host cells to secrete anti-inflammatory in-
terleukins (IL) such as IL-10, IL-3 and IL-13 [68].
Intrathecal delivery of hMSCs into SOD1G93A mice
slowed disease progression, but increased lymphocyte in-
filtration into the spinal cord [120]. However, hMSCs
cultured with peripheral blood mononuclear cells (PBMC)
derived from ALS patients increased the proportion of
regulatory T cells accompanied by enhanced production
of anti-inflammatory cytokines such as IL-4, IL-10 and
transforming growth factor-beta (TGFβ) [120]. Thus,
when injected into the cerebrospinal fluid (CSF) of ALS
mice, MSCs could exert their beneficial immunomodula-
tion by stimulating regulatory T cell proliferation, activa-
tion and migration to areas of CNS inflammation [120].
MSCs were shown to inhibit maturation and activation of
dendritic cells in vitro, and prevent lymphocyte migration
into the spinal cord of experimental autoimmune en-
cephalomyelitis mice [121, 122]. MSCs were also able
to suppress proliferation, maturation and activation of
pro-inflammatory Th1 and Th17 cells, with a concomitant
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switch toward active CD4+ CD25 Foxp3 regulatory T cells
in vitro [123].
T regulatory cells are reduced in patients with aggressive
ALS and reduced levels of these cells in early disease cor-
relates with rapid progression of neurodegeneration [124].
Interestingly, peripheral blood monocytes obtained from
ALS patients 4 h and 24 h after an intravenous infusion of
MSCs, showed a dramatic increase in CD4+ CD25+ regu-
latory T cells, coupled with a reduction in activated den-
dritic cells and lymphocyte proliferation [80].
The establishment of a sustained pro-inflammatory
milieu in ALS spinal cord has been demonstrated which
is probably accompanied by the shift of microglia cells
from an anti-inflammatory state (often referred to as M2
in the literature) to an active neurotoxic state (often re-
ferred to as M1 in the literature) [125].
Of interest, MSC-conditioned media significantly inhib-
ited the production and secretion of pro-inflammatory cy-
tokines in microglia activated by lipopolysaccharide (LPS)
[126] [127]. This, has been attributed to the capacity of
MSCs to secrete TGF-β, which in turn inhibited the NFκB
pathway and restored a protective microglial phenotype
[127]. Thus, through paracrine effects, MSCs could modu-
late the functional properties of microglia by switching the
detrimental M1 activated microglial state to the beneficial
M2 activated microglial state after LPS induction [127].
Therefore, the immunomodulatory properties of MSCs
may play an important role in attenuating neuroinflam-
matory processes during the progression of ALS and fur-
ther work is needed in order to explore this specific
mechanism.
An overview of the potential beneficial effects that
MSCs could exert in modulating pathophysiology in
neurodegenerative conditions is summarized in Fig. 3.
Delivery route for MSCs in ALS
One of the major technical issues in ALS cellular therapy
is to effectively deliver stem cells into the CNS. Several
studies demonstrated that injecting human stem cells
directly into the spinal cord of ALS rodents is feasible,
safe and efficient [40, 70, 71, 128]. The surgical proced-
ure for intraspinal infusion of hMSCs into the spinal
cord of ALS patients by specifically designed micro-
injection manipulators have also been shown to be safe
in open-label clinical trials [75, 76, 78, 79, 129]. How-
ever, direct CNS injection remains an invasive proced-
ure which could cause serious clinical complications
and permanent damage to CNS areas already affected
by the disease. Thus, it might be a considerable ethical
issue in clinical trials when investigating the efficacy of
the therapy, especially where placebo controls are
required.
Fig. 3 Potential mechanisms of mesenchymal stem cell efficacy in neurodegeneration. Transplanted MSCs may provide therapeutic responses
through paracrine effects and cell-to-cell contacts with resident neural cells. The capacity of MSCs to secrete cytokines, growth factors and exosomes
could potentially induce and support regeneration processes, including angiogenesis, synaptogenesis, axonal re-myelination and neurogenesis.
Because of their immunomodulatory properties, MSCs could attenuate inflammatory responses in the central nervous system by inhibiting
maturation and migration of dendritic cells, suppression of lymphocyte activation and proliferation, and by reducing gliosis. Moreover, MSCs
possess anti-apoptotic properties, and may limit excitotoxicity by modulating astrocyte functions
Ciervo et al. Molecular Neurodegeneration  (2017) 12:85 Page 14 of 22
Since early pathologic mechanisms of disease involve
destruction of neuromuscular junctions before motor
neuron death, intramuscular injection of MSCs at an
early stage of disease has also been proposed. Intramus-
cular injections of hMSCs engineered to overexpress
GDNF into SOD1G93A rats resulted in delayed disease
onset and prolonged survival, but MSCs were not able
to regenerate motor end-plates, nor to ameliorate motor
neuron loss [72].
Given the immunomodulatory properties, together
with the homing capacity in response to inflammatory
signals, hMSCs showed beneficial effects when infused
intravenously in ALS animal models [58, 61]. However,
even though intravenous infusion could be the easiest
and safest way for stem cell delivery, very few cells ap-
pear to be able to migrate, penetrate and engraft into
the spinal cord parenchyma. Thus, a large number of
cells may need to be transplanted in order to obtain ef-
fective results in human subjects.
The delivery of stem cells into the CSF surrounding
the spinal cord by intrathecal injection may be a useful
compromise, since stem cells would be placed in proxim-
ity to damaged areas without direct delivery into the spinal
cord parenchyma. Furthermore, it would be possible to
perform multiple injections both at the cervical and lum-
bar levels, allowing stem cells to migrate towards more af-
fected areas of neurodegeneration/inflammation [67]. In
some preclinical studies, stem cells were able to migrate
from the CSF into the parenchyma, however, the mecha-
nisms of migration remains unknown [64, 68]. Figure 4 is
a representation of different proposed strategies to deliver
MSCs into ALS patients with the relative advantages and
disadvantages.
Strategies to enhance tissue penetration
The study of CNS inflammation models allowed the dis-
covery of chemokines, receptors, adhesion molecules,
and inhibitors that govern and regulate lymphocyte mi-
gration, extravasation and penetration into the CNS par-
enchyma. Even though the migration of lymphocytes
from the blood to the CSF has been extensively studied,
very little is known about the transmigration of lympho-
cytes from the perivascular space to the CNS parenchyma,
where astrocytes and the basal membrane constitute a
second impermeable barrier [130].
Curiously, important chemokines released during in-
flammation which stimulate lymphocyte migration
through the BBB such as CXCL12 and CXCL10, were
shown to inhibit infiltration into the parenchyma, indu-
cing lymphocytes to persist in the perivascular space
[131, 132]. Conversely, production of metalloproteases
such as MP-2 and MP-9 seems to be necessary in order
to break the dystroglycan basal membrane required for
penetration into the CNS [130, 133].
MSCs express several chemokine receptors and hom-
ing properties similar to that of lymphocytes which allow
them to migrate into damaged or inflamed tissues. How-
ever, donor age and the number of passages in culture
were shown to negatively influence the stem cell’s ex-
pression of homing factors [134].
Interestingly, Corti and colleagues have performed
intrathecal and intravenous injection in SOD1G93A mice
of hiPSC-derived neural cells after being sorted for expres-
sion of the integrin VLA4 (CD49d) by FACS [49]. A con-
siderable number of transplanted cells were able to
migrate into the grey and white matter of spinal cord [49].
Engineering MSCs in order to induce overexpression
of chemokine receptors or factors involved in homing
and migration to sites of inflammation, may enhance
the delivery into the spinal cord parenchyma. The
characterization of chemokines and relative concentra-
tion in spinal cord and CSF of ALS models during dif-
ferent stages of disease would be of interest to identify
the best candidate and also the peak of inflammatory
chemokine production in order to define the ideal time
of intervention for stem cell injection.
Future directions in clinical trials
During the past two decades, several clinical trials inves-
tigated the use of stem cells in patients with ALS, mostly
focusing on the safety and feasibility of the intervention.
Nonetheless, as reported by Appel and Armon, stem cells
have often been transplanted into ALS patients with lim-
ited preclinical data, without providing details on adverse
effects and using small numbers of participants [135].
Moreover, the long-term safety of stem cell transplant-
ation (e.g. non acceleration of disease progression asso-
ciated with the cell implantation) has been evaluated by
comparison with historical control groups. This is an
important limitation since heterogeneity in the patient
population and differences in clinical care between the
treated group and historical controls may affect the
readouts [135].
Although single-armed, small phase I/II clinical trials
found that cell-based therapy for ALS is relatively safe
and feasible, it is uncertain whether stem cell transplant-
ation may be clinically beneficial leading to functional
improvements and of the slowing of disease progression.
The majority of the clinical trials were principally fo-
cused on the safety and feasibility of the surgical proced-
ure related to the stem cell implantation. Secondly, these
clinical trials were not powered to demonstrate any clin-
ical benefit [136].
In 2016, Abdul et al. published a systematic review
aiming to assess the effectiveness of stem cell therapy in
people with ALS, compared with a placebo or no
additional treatment [136]. However, the authors could
not identify any randomized controlled trial (RCT), quasi-
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RCT or cluster RCT involving the use of stem cells in
ALS/MND patients. Thus, there is an absence of high-
quality published evidence to assess the safety and efficacy
of stem cell transplantation in ALS [136]. Moreover, when
analyzing the single arm phase I/II clinical studies avail-
able in the literature, the authors found substantial vari-
ability between clinical trials in terms of selection criteria,
intervention methods and objective outcomes, with the
involvement of small number of participants and a short-
term follow-up period [136] .
To investigate the long-term safety and efficacy of
cellular therapy for ALS, well-designed prospective
randomized-controlled trials with larger sample size,
long-term-follow up and standardization of cell prod-
ucts, are urgently needed [136].
Recently, the ALS Clinical Trials Workshop (Airlie
Conference, Virginia, 2016), driven by the ALS commu-
nity, clinicians, researches, industry representatives,
government representatives, ALS patients and family
members, released and submitted to the FDA the draft
version of the “Guidance for Industry on Drug Devel-
opment for Amyotrophic Lateral Sclerosis”. The manu-
script has been drafted with the intention of improving
and accelerating the drug development process, includ-
ing guidelines for a more effective clinical trial design
in ALS [137]. In particular, the guideline highlighted
A
B
C
Fig. 4 Delivery strategies for the transplantation of MSCs in ALS. a Intrathecal delivery of MSCs into the spinal cord CSF; b Systemic delivery of
MSCs; c Local delivery of MSCs directly into the spinal cord parenchyma. For each delivery route, advantages and disadvantages are summarized
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the importance of reducing clinical and genetic hetero-
geneity when establishing the patient selection criteria.
With regards to clinical heterogeneity, inclusion and
exclusion criteria for patient enrolment must be well
justified for each study, which could vary depending on
the phase of development [137].
Selection criteria should also depend on the specific
trial goals, since some therapies may be more effective
in early stage of disease or in specific sub-group of pa-
tients. Thus, investigators should endeavor to incorpor-
ate reliable predictive and prognostic biomarkers for
clinical trial eligibility or stratification criteria [137].
Because of the multifactorial nature of ALS, post-hoc
analysis of reliable biological markers and neurophysio-
logical data is extremely important, since in specific sub-
groups of patients a beneficial effect could be missed dur-
ing the analysis. However, responder analyses must only
be used as hypothesis generating, which will need to be
confirmed and further investigated in future trials [137].
Importantly, although early phase trials are not meant
to investigate efficacy, for cell-based therapies which em-
brace potentially invasive delivery methods and lifelong
biological effects, evaluation of efficacy should be in-
cluded in the design of phase I trials. Furthermore, a
long-term monitoring plan to evaluate tumorigenesis,
stem cell engraftment and long-term efficacy should be
included [137].
Finally, RCTs with placebo controls is considered as
the gold standard for clinical investigation. However, in
rare, rapidly progressive and untreatable diseases such as
ALS, the requirement for a placebo could be revisited,
especially if the intervention involves invasive methods.
While in phase III clinical trials a randomized placebo
group is indispensable, in earlier phase studies, the use
of historical controls and predictive algorithms could be
accepted. However, the development of target-specific
biomarkers, standardization of outcome measures and
validation of surrogate end-points is essential, especially
in cell-based studies in which the mechanisms mediating
the therapeutic effect are not well established.
Conclusions
During the last decade, the great advances achieved in
regenerative medicine have created an unprecedented
enthusiasm and new hope for amelioration of the devas-
tating and until now incurable disease that is ALS. The
initial exciting idea of replacing lost of motor neurons,
with MSCs is unlikely to be achieved, although other
strategies may provide some promise for stem cell derived
motor neuron replacement [138]. Indeed, transplanted
cells should differentiate and integrate with the host
spinal motor circuits within the toxic and non-permissive
environment that characterizes ALS. However, the neuro-
protective and immunomodulatory potential of MSCSs
could match perfectly with the multifactorial nature of
ALS.
Among different types of stem cells, MSCs represent a
promising candidate for clinical application. However,
several technical issues need to be addressed including:
route of administration, optimal dose, and differentiation
state and neuroprotective mechanisms of transplanted
cells. In addition, in the majority of pre-clinical experi-
ments stem cell injection was performed before disease
onset. This is an important limitation for translation into
the clinic where the diagnosis takes several months and
early markers of disease are lacking [139]. Another limi-
tation is the exclusive use of the SOD1G93A model,
which may reflect the pathological features of only a very
small proportion of patients. Although these mice repre-
sent a robust model of ALS, only a small proportion of
ALS cases are caused by SOD1 mutations [140]. Thus,
the use of other ALS models such those driven by mutant
TDP-43 and C9ORF72 expansions would be of interest
[141].
Also, despite the excellent utility of the SOD1G93A
mice in revealing pathological ALS features, translation
of promising therapies from this model has failed in hu-
man clinical trials [142]. Apart from considerable differ-
ences between rodents and humans, the answer to this
problem could be attributed to the existence of a high
rate of intra- and inter-laboratory variability [142]. Such
variability could be improved by a more meticulous pre-
clinical design, use of defined inbred mouse strains, trans-
gene copy number analysis and trying to standardize
preclinical investigation methods [142, 143].
In general, the presence of injected stem cells within
the host nervous system of treated rodents was evaluated
only a few days or weeks post-transplantation. Thus, the
design of experiments looking at the long-term survival
and integration of cells is necessary.
Evaluation of the presence of injected cells in the host
has been carried out by the exclusive use of immunohis-
tochemistry. Adopting advanced microscopy techniques
such as confocal and two-photon microscopy would be
of great interest to confirm stem cell engraftment, which
could also allow tracking in vivo the fate of transplanted
cells [144, 145].
In addition, rate of proliferation, stemness properties,
longevity and differentiation capacity of MSCs declines
considerably with time when culturing cells as monolayers
[146]. The advent of 3D culture systems, along with enor-
mous progress in the fabrication of biomaterials must
be considered. When maintained in 3D culture sys-
tems such as hanging drops, low-adhesion plates, por-
ous scaffolds or hydrogels, hMSCs showed increased
proliferation and migration capacity, enhanced colony-
forming efficiency, higher expression of stem cell
markers, greater neuronal differentiation ability and
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greater cellular engraftment after transplantation in
animals [146–148].
Thus, the regenerative potential of stem cells could be
considerably improved by adopting 3D culture methods.
Transplantation of bio-scaffolds or encapsulating MSCs
to sustain favorable conditions for stem cell survival,
growth, migration and maturation is showing promising
results in experimental models of spinal cord injury,
traumatic brain injury and nerve regeneration, and must
be considered in ALS models where the presence of a
hostile microenvironment is one of the main factors that
negatively affects stem cell engraftment and therefore
therapeutic potential [147, 149, 150].
The optimal maturation level for the transplantation
of stem cells to obtain the greatest therapeutic benefit is
also unclear. If undifferentiated cells may represent the
best way to obtain immunomodulation and trophic fac-
tor production, induced neural progenitors may over-
come the possibility of tumour formation, along with the
possibility of in vivo maturation and integration into
existing neuronal circuits.
A combination strategy could be interesting, where
intravenous infusion of immature cells may generate
permissive environmental conditions for the successive
implantation of neuronal committed cells within the
CSF. This would require an in-depth study of the matur-
ation process of MSCs into neurons, trying to under-
stand, optimize and standardize differentiation protocols
that promote the generation of stable precursors.
Last but not least, although autologous transplantation
can reduce the probability of immune rejection, it has
been reported that patient-derived MSCs may have im-
paired or reduced therapeutic effects [151, 152]. Other
evidence indicates no functional alteration or accelerated
cellular senescence in BM-MSCs derived from sporadic
cases of ALS [153]. Moreover, it was shown that there
was the possibility to functionally restore defective
ALS-derived MSCs by correcting alterations in DNA
methylation [153, 154]. However, the identification of
MSC biological markers predictive of a positive/negative
therapeutic response in ALS patients would be of great
value [82]. In relation to the use of autologous MSCs in
patients carrying ALS causative genetic mutations, stem
cells could be genetically corrected by adopting CRISPR-
Cas9-mediated gene editing technology [155].
In conclusion, several strategies have been tested in
the SOD1G93A mouse model, but with different hurdles.
All the discussed parameters should be reconsidered and
optimized before the translation of stem cell therapy
from mice to humans in order to avoid undesirable de-
lays or therapy failure as has happened for most of the
promising results derived from SOD1G93A transgenic
mouse models, with failure of translation into clinical
benefits for ALS patients.
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